NervGen Pharma Corp. (NGEN) Live Share Price, Invest From India

NervGen Pharma Corp. Stock Performance

as on June 6, 2026 at 2:16 pm IST

Day's Low
Day's High
$1.85
Day's Price Range
$2.05
$1.86
0.54%
Downside
10.22%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$1.86
100.00%
Downside
-100.00%
Upside

NervGen Pharma Corp. share price movements today

Previous Close: $2.01
Open: $2.01
Volume: 1.9M
Day's Low - High: $1.85 - $2.05

NervGen Pharma Corp. Historical Returns

1 Month Return: -46.68 %
3 Month Return: -50.25 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

NervGen Pharma Corp. Stock Fundamentals & Key Indicators

Check NervGen Pharma Corp. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$202.8M

EPS (TTM)

-0.2615

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-1207.46%

NervGen Pharma Corp. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of NervGen Pharma Corp. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
NervGen Pharma Corp.	NA	$202.8M	NA	NA	0.00%	NA
Revolution Medicines Inc	BUY	$32.2B	410.63%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc	BUY	$39.1B	108.54%	73.51	12.55%	NA
Vertex Pharmaceuticals Inc	BUY	$108.7B	110.42%	25.45	35.51%	NA
Regeneron Pharmaceuticals Inc	BUY	$64.9B	22.83%	15.11	29.65%	0.59%

Indian Investors' Interest in NervGen Pharma Corp. Stock

Search interest for NervGen Pharma Corp. Stock has increased by 64% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 8, 2026 to June 7, 2026

Change:64% versus previous 30 day period

NervGen Pharma Corp. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0
Operating Income	-4	-4	-6	-6	-11	-7
EBITDA	-5	-2	-9	-4	6	-7
Interest Expense	-	-	-	-	-	-
Depreciation	0	0	0	0	0	-
Income Before Tax	-5	-2	-9	-4	-31	-1
Income Tax Expense	-	-	-	-	-	-
Net Income	-4	-1	-9	-4	-31	-1
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

NervGen Pharma Corp. Annual Profit & Loss

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-
Gross Profit	0	0	0	-
Operating Income	-22	-17	-24	-25
EBITDA	-19	-22	-23	-5
Interest Expense	0	-	-	-
Depreciation	0	0	0	0
Income Before Tax	-20	-22	-23	-44
Income Tax Expense	-	-	-	-
Net Income	-15	-16	-16	-44
Net Profit Margin	0.00%	0.00%	0.00%	0.00%

NervGen Pharma Corp. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-1	-5	-3	-5	-2	-9	-4	-31	-1
Operating Cash Flow	-2	-3	-4	-2	-2	-3	-5	-10	-8
Investing Cash Flow	-	0	0	0	0	0	0	0	0
Financing Cash Flow	16	0	0	0	0	4	0	18	2
Change in Cash	13	-2	-3	-3	-1	1	-4	13	-5

NervGen Pharma Corp. Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-7	-8	-10	-20	-22	-23	-44
Operating Cash Flow	-6	-4	-6	-17	-11	-16	-19
Investing Cash Flow	-	0	0	0	0	0	0
Financing Cash Flow	7	6	15	22	0	22	23
Change in Cash	1	1	8	4	-10	4	4

Global Institutional Holdings in NervGen Pharma Corp.

Funds	Holdings
Almanack Investment Partners, LLC.	0.03%
Traynor Capital Management, Inc	0.03%
PFG Investments, LLC	0.25%
Bank of America Corp	0.25%
Marshall Wace Asset Management Ltd	0.25%

See all

Insights on NervGen Pharma Corp.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NEGATIVE IMPACT
Price Dip
In the last 1 month, NGEN stock has moved down by -51.7%

About NervGen Pharma Corp.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Organisation	NervGen Pharma Corp.
Headquarters	112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4
Industry	Biotechnology
CEO	Dr. Adam H. Rogers M.D.
E-voting on shares	Click here to vote

Key Management of NervGen Pharma Corp.

Name	Title
Ms. Shamim Ruff M.S.	Chief Regulatory Affairs Officer
Ms. Christine McSherry	Senior Vice President of Patient Advocacy & Clinical Affairs
Dr. Adam H. Rogers M.D.	President, CEO & Chairman
Dr. Harold Martin Punnett D.M.D.	Co-Founder & Independent Director
Dr. Randall E. Kaye M.D.	Chief Medical Advisor & Director
Dr. Keith A. Vendola M.B.A., M.D.	Chief Financial Officer

FAQs

What is NervGen Pharma Corp. share price today?

NervGen Pharma Corp. share price today is $1.86 as on June 6, 2026 at 8:46 am IST at the close of the market. NervGen Pharma Corp. share today touched a day high of $2.05 and a low of $1.85.

What is the 52 week high and 52 week low for NervGen Pharma Corp. share?

NervGen Pharma Corp. share touched a 52 week high of $0 on January 1, 1970 and a 52 week low of $0 on January 1, 1970. NervGen Pharma Corp. stock price today i.e. June 6, 2026 at 8:46 am IST is closed at $1.86,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is NervGen Pharma Corp.'s market capitalisation today?

NervGen Pharma Corp. market capitalisation is $0.00T as on June 6, 2026 at 8:46 am IST.

How to invest in NervGen Pharma Corp. Stock (NGEN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for NervGen Pharma Corp. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in NervGen Pharma Corp. Shares that will get you 0.8065 shares as per NervGen Pharma Corp. share price of $1.86 per share as on June 6, 2026 at 8:46 am IST.

What is the minimum amount required to buy NervGen Pharma Corp. Stock (NGEN) from India?

Indian investors can start investing in NervGen Pharma Corp. (NGEN) shares with as little as ₹94.95 or $1 (as of June 7, 2026 at 9:01 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹949.50 in NervGen Pharma Corp. stock (as per the Rupee-Dollar exchange rate as on June 7, 2026 at 9:01 am IST). Based on NervGen Pharma Corp. share’s latest price of $1.86 as on June 6, 2026 at 8:46 am IST, you will get 5.3763 shares of NervGen Pharma Corp.. Learn more about fractional shares .